BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Feld JJ, Foster GR. Second generation direct-acting antivirals – Do we expect major improvements? Journal of Hepatology 2016;65:S130-42. [DOI: 10.1016/j.jhep.2016.07.007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Madden A, Hopwood M, Neale J, Treloar C. Beyond cure: patient reported outcomes of hepatitis C treatment among people who inject drugs in Australia. Harm Reduct J 2018;15:42. [PMID: 30111327 DOI: 10.1186/s12954-018-0248-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
2 Serranti D, Indolfi G, Nebbia G, Cananzi M, D'Antiga L, Ricci S, Stagi S, Azzari C, Resti M; Italian Study Group for Treatment of Chronic Hepatitis C in Children. Transient Hypothyroidism and Autoimmune Thyroiditis in Children With Chronic Hepatitis C Treated With Pegylated-interferon-α-2b and Ribavirin. Pediatr Infect Dis J 2018;37:287-91. [PMID: 28953189 DOI: 10.1097/INF.0000000000001791] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
3 Wang H, Xin X, Wang M, Han L, Li J, Hao Y, Zheng C, Shen C. Myxovirus resistance protein A inhibits hepatitis C virus replication through JAK-STAT pathway activation. Arch Virol 2018;163:1429-38. [PMID: 29417241 DOI: 10.1007/s00705-018-3748-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
4 Marshall AD, Grebely J, Dore GJ, Treloar C. ‘I didn’t want to let it go too far.’ The decisions and experiences of people who inject drugs who received a liver disease assessment as part of a liver health promotion campaign: The LiveRLife study. International Journal of Drug Policy 2017;47:153-60. [DOI: 10.1016/j.drugpo.2017.06.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
5 Madden A, Hopwood M, Neale J, Treloar C. Beyond interferon side effects: What residual barriers exist to DAA hepatitis C treatment for people who inject drugs? PLoS One 2018;13:e0207226. [PMID: 30500863 DOI: 10.1371/journal.pone.0207226] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 7.8] [Reference Citation Analysis]
6 Godin A, Kronfli N, Cox J, Alary M, Maheu-Giroux M. The role of prison-based interventions for hepatitis C virus (HCV) micro-elimination among people who inject drugs in Montréal, Canada. Int J Drug Policy 2021;88:102738. [PMID: 32278651 DOI: 10.1016/j.drugpo.2020.102738] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
7 Elhefnawi M, Jo E, Tolba MM, Fares M, Yang J, Shahbaaz M, Windisch MP. Drug repurposing through virtual screening and in vitro validation identifies tigecycline as a novel putative HCV polymerase inhibitor. Virology 2022. [DOI: 10.1016/j.virol.2022.02.006] [Reference Citation Analysis]
8 Gonzalez SA, Fierer DS, Talal AH. Medical and Behavioral Approaches to Engage People Who Inject Drugs Into Care for Hepatitis C Virus Infection. Addict Disord Their Treat. 2017;16:S1-S23. [PMID: 28701904 DOI: 10.1097/adt.0000000000000104] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 4.2] [Reference Citation Analysis]
9 Lee DH, Ryu SH, Myung HJ, Shin YJ, Lee SH, Park TY, Moon JS. Retreatment of Chronic Hepatitis C Failed to Daclatasvir Plus Asunaprevir by Other Direct-acting Antivirals. Korean J Gastroenterol 2021;77:88-91. [PMID: 33633000 DOI: 10.4166/kjg.2020.145] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Marshall AD, Pawlotsky J, Lazarus JV, Aghemo A, Dore GJ, Grebely J. The removal of DAA restrictions in Europe – One step closer to eliminating HCV as a major public health threat. Journal of Hepatology 2018;69:1188-96. [DOI: 10.1016/j.jhep.2018.06.016] [Cited by in Crossref: 53] [Cited by in F6Publishing: 53] [Article Influence: 13.3] [Reference Citation Analysis]
11 Kronfli N, Cox J. Care for people with hepatitis C in provincial and territorial prisons. CMAJ 2018;190:E93-4. [PMID: 29378868 DOI: 10.1503/cmaj.171142] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
12 Chan H, Hassali MA, Md Said R, Omar H, Abd Mutalib NA, De Rozario FW, Abu Hassan MR. A Two-Year Outcome Evaluation of Government-Led Initiative to Upscale Hospital-based Hepatitis C Treatment Using a Standard Two-Drug Regimen in Malaysia. Hepat Mon 2021;21. [DOI: 10.5812/hepatmon.113226] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
13 Tran TN, Nguyen NT. In Silico Screening for Potent Anti-HCV Compounds with Inhibitory Activities Toward the NS3/4A Protease. Int J Pept Res Ther 2019;25:1033-40. [DOI: 10.1007/s10989-018-9750-5] [Reference Citation Analysis]
14 Kazmierski WM, Miriyala N, Johnson DK, Baskaran S. The Discovery of Conformationally Constrained Bicyclic Peptidomimetics as Potent Hepatitis C NS5A Inhibitors. ACS Med Chem Lett 2021;12:1649-55. [PMID: 34790290 DOI: 10.1021/acsmedchemlett.1c00391] [Reference Citation Analysis]
15 Bulankina AV, Richter RM, Welsch C. Regulatory Role of Phospholipids in Hepatitis C Virus Replication and Protein Function. Pathogens 2022;11:102. [DOI: 10.3390/pathogens11010102] [Reference Citation Analysis]
16 Jacobson IM, Lawitz E, Gane EJ, Willems BE, Ruane PJ, Nahass RG, Borgia SM, Shafran SD, Workowski KA, Pearlman B, Hyland RH, Stamm LM, Svarovskaia E, Dvory-Sobol H, Zhu Y, Subramanian GM, Brainard DM, McHutchison JG, Bräu N, Berg T, Agarwal K, Bhandari BR, Davis M, Feld JJ, Dore GJ, Stedman CAM, Thompson AJ, Asselah T, Roberts SK, Foster GR. Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials. Gastroenterology 2017;153:113-22. [PMID: 28390869 DOI: 10.1053/j.gastro.2017.03.047] [Cited by in Crossref: 170] [Cited by in F6Publishing: 139] [Article Influence: 34.0] [Reference Citation Analysis]
17 Sarwar S, Khan AA. Sofosbuvir based therapy in hepatitis C patients with and without cirrhosis: Is there difference? Pak J Med Sci 2017;33:37-41. [PMID: 28367169 DOI: 10.12669/pjms.331.12163] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
18 Angeletti A, Cantarelli C, Cravedi P. HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents. Front Med (Lausanne) 2019;6:20. [PMID: 30800660 DOI: 10.3389/fmed.2019.00020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
19 Nguyen K, Jimenez M, Moghadam N, Wu C, Farid A, Grotts J, Elashoff D, Choi G, Durazo FA, El-Kabany MM. Decrease of Alpha-fetoprotein in Patients with Cirrhosis Treated with Direct-acting Antivirals. J Clin Transl Hepatol. 2017;5:43-49. [PMID: 28507926 DOI: 10.14218/jcth.2016.00057] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
20 Butt N, Akbar A, Abbasi A, Reema S, Baqar JB, Shaikh QH. Safety and Efficacy of Sofosbuvir with Ribavirin® in Hepatitis C, Genotype 3 Patients with Cirrhosis: A Real-world Experience. Cureus 2019;11:e4012. [PMID: 31001466 DOI: 10.7759/cureus.4012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Sarhan M, El-Bitar AMH, Hotta H. Potent virucidal activity of honeybee "Apis mellifera" venom against Hepatitis C Virus. Toxicon 2020;188:55-64. [PMID: 33068557 DOI: 10.1016/j.toxicon.2020.10.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Ellwanger JH, Kaminski VL, Valverde-Villegas JM, Simon D, Lunge VR, Chies JAB. Immunogenetic studies of the hepatitis C virus infection in an era of pan-genotype antiviral therapies - Effective treatment is coming. Infect Genet Evol 2018;66:376-91. [PMID: 28811194 DOI: 10.1016/j.meegid.2017.08.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
23 Madden A, Hopwood M, Neale J, Treloar C. Acceptability of Patient-Reported Outcome and Experience Measures for Hepatitis C Treatment Among People Who Use Drugs. Patient 2019;12:259-65. [PMID: 30270403 DOI: 10.1007/s40271-018-0332-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
24 Felsher M, Tobin KE, Sulkowski M, Latkin C, Falade-Nwulia O. HCV communication within ego-centric networks of men and women who inject drugs. Drug Alcohol Depend 2021;229:109157. [PMID: 34740020 DOI: 10.1016/j.drugalcdep.2021.109157] [Reference Citation Analysis]